Form 8.5 Disclosure by Alliance Pharma
FORM 8.5 DISCLOSURE
This publication is to inform stakeholders about crucial dealings made by an exempt principal trader in a client-serving capacity. This disclosure is made under Rule 8.5 of the Takeover Code.
Key Information Regarding Trading Activity
The exempt principal trader involved is Investec Bank plc. They are facilitating dealings in relation to the relevant securities of Alliance Pharma plc. Such transparency is vital to maintaining integrity within the trading markets.
Parties Involved in This Disclosure
This particular trading activity involves Aegros Bidco Limited, which is financially advised by Investec Bank plc. They are associated with the acquisition process and provide necessary finance related to the trading of relevant securities.
Date of Trading Activity
The transactions outlined in this disclosure were undertaken on a specified date, marking the beginning of engagements related to the shares of Alliance Pharma plc. It is important for stakeholders to note these interactions reflect the ongoing market activities.
Details of the Dealings
When analyzing trading activities, it is important to categorize them effectively. Below is a breakdown of the purchases and sales made by the exempt principal trader:
Purchases and Sales Overview
In the relevant security class, it was reported that the exempt principal trader made significant transactions. They purchased 1,454,394 ordinary shares at a price range of 62.5 per unit with the lowest recorded price being 62.2. Conversely, they sold 1,560,010 ordinary shares at maximum rates of 62.5, with the lowest price observed at 62.35.
Derivative Transactions
Though there were no cash-settled derivative transactions reported, it is essential to monitor any future dealings as they can significantly influence stock price movements. This section keeps market issuers accountable and informed.
Additional Information
In regards to other dealings, including options or futures which were either subscribed for or converted, no relevant transactions were identified at the time of this disclosure.
Indemnity Arrangements
Currently, it appears there are no formal agreements or informal understandings associated with indemnities, which ensures a level of clarity and trust in the interactions made.
Future Communications
The Contact Name for any inquiries regarding this disclosure is Priyali Bhattacharjee. If you wish to discuss specifics regarding these trading activities further, they can be reached via telephone at +91 9768034903.
Frequently Asked Questions
What is the purpose of this Form 8.5 disclosure?
The purpose of this disclosure is to inform stakeholders about significant trading activities undertaken by an exempt principal trader on behalf of Alliance Pharma plc.
Who is the exempt principal trader mentioned in the disclosure?
The exempt principal trader is Investec Bank plc, acting in a client-serving capacity for Alliance Pharma plc.
What types of transactions were reported?
The transactions reported include both purchases and sales of ordinary shares, along with any derivative activities if applicable.
Has there been any significant change in the share price?
Yes, the disclosure highlights various purchase and sale prices reflecting changes in valuation depending on the number of securities in the transactions.
How can I contact the company for more information?
For further inquiries, you can reach Priyali Bhattacharjee at +91 9768034903, who is noted as the contact person for this matter.
